2022 and the year ahead – CERA

As we start another year, we speak to professionals across the eye health industry to understand the challenges, opportunities, trends and priorities for the...

CERA – Preserving sight in pregnancy

A CERA researcher’s PhD could help prevent sight loss during pregnancy in women with types 1 and 2 diabetes. Her research may also influence...

Future vision

The Australian bionic eye has captured the world’s attention after a landmark clinical trial at CERA showed that it’s capable of improving functional vision...

Switching on sight

More than 126 million photoreceptors form part of the complex layers of cells that make up the retina at the back of our eye. The...

CERA: Seeking a smarter way to monitor glaucoma

Dr George Kong is developing new technology to keep patients out of crowded waiting rooms and make smartphones a vital weapon in the battle...

How COVID-19 is changing the future of eye care

The rapid uptake of telehealth services to stop the spread of coronavirus is adding impetus to research to develop innovative new ways of diagnosing and monitoring patients with eye disease.

Could artificial intelligence be beneficial in screening for eye disease?

Centre for Eye Research Australia (CERA), in conjunction with the University of Melbourne is conducting research to gain a better understanding of how artificial intelligence (AI) influences clinical decision-making by a range of health professionals engaged in diabetic retinopathy (DR) screening.

Hot topics in research: Reticular pseudodrusen

15 CPD Minutes in Australia Researchers believe the presence of reticular pseudodrusen may provide valuable insights into a patient’s likely progression to late stage age-related macular degeneration (AMD).

Artificial intelligence boosts the battle against diabetic eye disease

15 CPD Minutes in Australia Artificial intelligence is being deployed in research to help the 1.3 million Australians with diabetes avoid sight threatening complications.

Promising vitamin B3 glaucoma research

AU: 15 minutes CPD CERA's research is the first clinical study to demonstrate the potential of vitamin B3 as a glaucoma therapy.